OMER
Price:
$7.15
Market Cap:
$415.16M
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs...[Read more]
Industry
Biotechnology
IPO Date
2009-10-08
Stock Exchange
NASDAQ
Ticker
OMER
According to Omeros Corporation’s latest financial reports and current stock price. The company's current ROE is 117.75%. This represents a change of 248.40% compared to the average of 33.80% of the last 4 quarters.
The mean historical ROE of Omeros Corporation over the last ten years is 378.37%. The current 117.75% ROE has changed -68.88% with respect to the historical average. Over the past ten years (40 quarters), OMER's ROE was at its highest in in the December 2021 quarter at 1.18%. The ROE was at its lowest in in the June 2023 quarter at -181.83%.
Average
378.37%
Median
132.06%
Minimum
-19.50%
Maximum
1.90%
Discovering the peaks and valleys of Omeros Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.06%
Maximum Annual ROE = 1.90%
Minimum Annual Increase = -174.64%
Minimum Annual ROE = -19.50%
Year | ROE | Change |
---|---|---|
2024 | 85.87% | -81.79% |
2023 | 471.57% | 1.30% |
2022 | 33.59% | -95.89% |
2021 | 816.80% | 5.06% |
2020 | 15.82% | 8.71% |
2019 | 14.55% | -174.64% |
2018 | -19.50% | -101.03% |
2017 | 1.90% | 966.29% |
2016 | 178.24% | -37.73% |
2015 | 286.25% | 65.73% |
The current ROE of Omeros Corporation (OMER) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
197.01%
5-year avg
284.73%
10-year avg
378.37%
Omeros Corporation’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-30.90%), greater than Enanta Pharmaceuticals, Inc. (-75.53%), greater than Amicus Therapeutics, Inc. (-35.28%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than Connect Biopharma Holdings Limited (-21.00%), greater than Ligand Pharmaceuticals Incorporated (-0.50%), greater than Passage Bio, Inc. (-78.64%), greater than ORIC Pharmaceuticals, Inc. (-44.54%), greater than Lyell Immunopharma, Inc. (-65.86%), greater than Design Therapeutics, Inc. (-19.34%), greater than Revolution Medicines, Inc. (-33.45%), greater than Akero Therapeutics, Inc. (-32.18%), greater than Avidity Biosciences, Inc. (-25.89%), less than Protagonist Therapeutics, Inc. (47.67%), greater than Stoke Therapeutics, Inc. (-42.16%), greater than Arcutis Biotherapeutics, Inc. (-77.20%), greater than Icosavax, Inc. (-20.22%), greater than Mirum Pharmaceuticals, Inc. (-38.18%), greater than VectivBio Holding AG (-56.92%), greater than Day One Biopharmaceuticals, Inc. (-22.99%), greater than Biomea Fusion, Inc. (-150.95%), greater than Homology Medicines, Inc. (-100.91%), greater than Gossamer Bio, Inc. (-117.84%),
Company | ROE | Market cap |
---|---|---|
-30.90% | $2.91B | |
-75.53% | $117.33M | |
-35.28% | $2.12B | |
-98.94% | $8.19B | |
-21.00% | $38.73M | |
-0.50% | $2.05B | |
-78.64% | $21.75M | |
-44.54% | $370.76M | |
-65.86% | $135.83M | |
-19.34% | $224.78M | |
-33.45% | $6.85B | |
-32.18% | $3.07B | |
-25.89% | $3.54B | |
47.67% | $2.81B | |
-42.16% | $498.60M | |
-77.20% | $1.64B | |
-20.22% | $769.04M | |
-38.18% | $1.95B | |
-56.92% | $1.06B | |
-22.99% | $742.92M | |
-150.95% | $73.27M | |
-100.91% | $3.02M | |
-117.84% | $188.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Omeros Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Omeros Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Omeros Corporation's ROE?
How is the ROE calculated for Omeros Corporation (OMER)?
What is the highest ROE for Omeros Corporation (OMER)?
What is the 3-year average ROE for Omeros Corporation (OMER)?
What is the 5-year average ROE for Omeros Corporation (OMER)?
How does the current ROE for Omeros Corporation (OMER) compare to its historical average?